Romanos SP

MD-PhD, Asst. Professor @cityofhope, previously @DanaFarber @broadinstitute. Founder @PredictaBiosci. 🏳️‍🌈 (he/him) #mmsm #wmsm #lymsm

[Romanos SP @RomanosSP]

Very excited to share our new story in @NatureCancer! Together w/ Liz, we found a great way to sensitively detect *and* molecularly characterize circulating tumor cells (CTCs) in patients with Multiple Myeloma (MM) and its precursor conditions! #mmsm /1
https://t.co/Ukw3uzVOx1

[Blood Cancers Today @Blood_Cancers]

🙌 ICYMI: @IrenemGhobrial and @RomanosSP, of @DanaFarber, discussed a novel, single cell, sequencing-based blood test for multiple myeloma called SWIFT-seq that can enable molecular profiling from the blood.

📺 Watch here: https://t.co/9DIw8VMYGO

[Dr. Patrick Hwu @PatrickHwuMD]

#ScienceSaturday

❓ Some people with multiple myeloma respond well to CAR T-cell therapy, but others relapse when the cancer finds ways to hide. Why does that happen, and how can we fix it?

➡️ Dr. Fabiana Perna and colleagues at Moffitt Cancer Center, found that one reason is that some myeloma cells don’t have enough of a target protein called BCMA, which CAR T cells need to find and attack the cancer.

➡️ To solve this, the team designed a new kind of CAR T cell that looks for a different target called SEMA4A. This protein is common on myeloma cells—even in patients whose cancer came back after BCMA-CAR T therapy.

➡️ In lab and mouse studies, these SEMA4A-CAR T cells destroyed myeloma cells that regular BCMA-CAR T cells couldn’t reach, showing promise for treating relapsed patients in the future.

🌟 This research could lead to next-generation cell therapies that keep multiple myeloma from coming back and help more patients stay cancer-free longer. @fabianaperna @MoffittNews

🔗 Read more in Cancer Cell: https://t.co/Cr0ZJDB9Ei

[Romanos SP @RomanosSP]

@FrancescoMaura4 @JCO_ASCO @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic Congrats Francesco and team!

[Francesco Maura @FrancescoMaura4]

Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14

[Illumina Ventures @illuminaventure]

🎉Congrats to portfolio company @PredictaBiosci on the close of a $23.4 million #SeriesA and appointment of CEO Brian McKernan. The funding will support development of #diagnostics for blood cancers and autoimmune diseases.

📢 Announcement: https://t.co/x9IlXlaEnz

#PartnerNews

[Romanos SP @RomanosSP]

@juanjogrcs @Hemasphere_EHA @somersault1824 Congrats @juanjogrcs @BenDiamondMD @FrancescoMaura4 @TomasJelinekMD! 👏🏻

[Juanjo Garcés @juanjogrcs]

As we promised, finally the paper is out!

👉Elevated #CTCs reflect high proliferation and genomic complexity in #mmsm

https://t.co/VgFEyFNLOq

[Kate Sears @MedwatchKate]

Hi friends, it's #Myeloma Monday! Here are Top Posts of the Week 🧵

1/ @tarekmd91 on joining the faculty at Dana Farber:
https://t.co/X5vxxdSvr9

[Romanos SP @RomanosSP]

@tarekmd91 @DanaFarber ❤️

[Romanos SP @RomanosSP]

@mtmdphd @IrenemGhobrial @LabGhobrial @NatureCancer Thanks for sharing!

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma & its precursors [Aug 8, 2025] Lightbody, @RomanosSP et al.
@IrenemGhobrial - @LabGhobrial @NatureCancer
https://t.co/LhqmRShFo9 #mmsm #LiquidBiopsy #cactc

[Romanos SP @RomanosSP]

@FrancescoMaura4 @NatureGenet @HDMyeloma @SylvesterCancer @MayoClinic @MSKCancerCenter @MSK_DeptOfMed Congrats @FrancescoMaura4 and team! 🎉

[Francesco Maura @FrancescoMaura4]

Excited to share our new paper, out today on @NatureGenet where we use 421 #WGS to reconstruct the evolutionary history of multiple myeloma #mmsm (🔥🔥). Great collaboration with @HDMyeloma @SylvesterCancer @MayoClinic @MSKCancerCenter @MSK_DeptOfMed ⁦.

[Nature Cancer @NatureCancer]

🚨 New article alert! 🚨 Check out our last release by @IrenemGhobrial and colleagues on "SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors" @DanaFarber

👉https://t.co/G0FX5UY6PK

[Science in Boston @ScienceinBoston]

Drs. @IrenemGhobrial, @RomanosSP, and Elizabeth Lightbody at @DanaFarber have developed a blood test that could transform the diagnosis and monitoring of #MultipleMyeloma and its precursor conditions.

Press release: https://t.co/MEcrNt7cOJ
@NatureCancer: https://t.co/5GI872dvTo

[OncoDaily @oncodaily]

Myeloma Paper of the Day, August 10th, Suggested by Robert Orlowski (@Myeloma_Doc)

@IrenemGhobrial @NatureCancer

https://t.co/hbwOmJUmDG

#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #SWIFTseq @CancerWorldmag

[Romanos SP @RomanosSP]

@NorthTxMSG Thanks for sharing our work!

[Yelak Biru @NorthTxMSG]

SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Dr. @IrenemGhobrial #mmsm https://t.co/4cHNQ0k5J2

[Romanos SP @RomanosSP]

@juanjogrcs @LabGhobrial Thanks for sharing! 🤓

[Juanjo Garcés @juanjogrcs]

Through cutting-edge scRNAseq, @LabGhobrial confirms the potential of #CTCs for minimally invasive genomic profiling in #mmsm! 💪🩸
https://t.co/yDqWQXdP5W